M2Gen sets benchmark with $7.3M federal contract
Moffitt Cancer Center and M2Gen will play a central role in a new study of a group of blood disorders.
The National Institutes of Health's National Heart, Lung, and Blood Institute awarded Moffitt and its for-profit subsidiary, M2Gen, a contract to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study.
The $7.3 million project is the first federally funded contract for biorepository services at M2Gen, Moffitt's for-profit subsidiary,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Margie Manning Source Type: news
More News: American Health | Cancer | Cancer & Oncology | Cardiology | Contracts | Health | Health Management | Heart | Laboratory Medicine | Myelodysplastic Syndrome | National Institutes of Health (NIH) | Study